What Even Is ‘Moderate’ IBD? Experts Can’t Agree emjreviews.com

What Even Is ‘Moderate’ IBD? Experts Can’t Agree

2 min read
Research and clinical trials Clinical study Clinicians Researchers Adult patients Newly Diagnosed Crohn's disease Ulcerative colitis
Why This Matters

How “moderate” IBD is defined affects who is enrolled in trials, who is offered advanced therapies, and how clinicians make treatment decisions. Inconsistent definitions could delay appropriate care for people who might benefit from earlier escalation.

Who Should Pay Attention

Clinicians who treat IBD, researchers designing trials or registries, adult patients and caregivers interested in disease classification and treatment thresholds, and those newly diagnosed who want to understand how severity is judged.

What To Know

This news piece reports a review study that found large, inconsistent variations in how “moderate” IBD is defined across trials and observational studies for both Crohn’s disease and ulcerative colitis.

The article highlights reliance on scoring tools (CDAI, Mayo) with differing thresholds and notes that important patient-centered factors — quality of life, prognosis, and disease trajectory — are often omitted from definitions.

The study reviewed >240 publications and identified multiple competing definitions (six for Crohn’s, 16 for UC) that sometimes overlap with thresholds used for severe disease. Authors and experts argue a unified, clinically relevant definition is needed to inform treatment decisions and to identify patients who may benefit from earlier biologic therapy.

The article does not report new trial data or specific treatment changes; it summarizes the review’s findings and expert commentary. Practical takeaway: This is about how researchers and clinicians categorize disease severity, not a new treatment or guideline.

It may influence future research, trial design, and how clinicians decide on escalation of therapy, but it does not itself change clinical recommendations.

Keep In Mind

This article summarizes a review published in Journal of Clinical Gastroenterology. Findings point to the need for broader, patient-centered severity criteria but do not provide a new consensus definition or immediate clinical guidance.

Study limitations, such as heterogeneity of included publications and lack of prospective testing of proposed frameworks, are implied; readers should consult the original paper for full methods and details.

This Cure8 note is AI-assisted and based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Read Original Article Originally published Apr 22, 2026, 7:57 AM
Advertisement Space

Related Articles